                         SEQUENCE LISTING

<110>  MINERVA BIOTECHNOLOGIES CORPORATION
 
<120>  DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES

<130>  13150-70156PCT

<150>  62/635,378
<151>  2018-02-26

<150>  62/640,697
<151>  2018-03-09

<150>  PCT/US18/62569
<151>  2018-11-27

<150>  62/791,661
<151>  2019-01-11

<160>  386   

<170>  PatentIn version 3.5

<210>  1
<211>  1255
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Full-length MUC1 Receptor (Mucin 1 precursor, Genbank Accession 
       number: P15941

<400>  1

Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr 
1               5                   10                  15      


Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly 
            20                  25                  30          


Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser 
        35                  40                  45              


Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His 
    50                  55                  60                  


Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu 
65                  70                  75                  80  


Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln 
                85                  90                  95      


Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr 
            100                 105                 110         


Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro 
        115                 120                 125             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    130                 135                 140                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
145                 150                 155                 160 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                165                 170                 175     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            180                 185                 190         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        195                 200                 205             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    210                 215                 220                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
225                 230                 235                 240 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                245                 250                 255     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            260                 265                 270         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        275                 280                 285             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    290                 295                 300                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
305                 310                 315                 320 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                325                 330                 335     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            340                 345                 350         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        355                 360                 365             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    370                 375                 380                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
385                 390                 395                 400 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                405                 410                 415     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            420                 425                 430         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        435                 440                 445             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    450                 455                 460                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
465                 470                 475                 480 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                485                 490                 495     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            500                 505                 510         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        515                 520                 525             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    530                 535                 540                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
545                 550                 555                 560 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                565                 570                 575     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            580                 585                 590         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        595                 600                 605             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    610                 615                 620                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
625                 630                 635                 640 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                645                 650                 655     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            660                 665                 670         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        675                 680                 685             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    690                 695                 700                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
705                 710                 715                 720 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                725                 730                 735     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            740                 745                 750         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        755                 760                 765             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    770                 775                 780                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
785                 790                 795                 800 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                805                 810                 815     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            820                 825                 830         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        835                 840                 845             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 
    850                 855                 860                 


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 
865                 870                 875                 880 


Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 
                885                 890                 895     


Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 
            900                 905                 910         


Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 
        915                 920                 925             


Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Asn 
    930                 935                 940                 


Arg Pro Ala Leu Gly Ser Thr Ala Pro Pro Val His Asn Val Thr Ser 
945                 950                 955                 960 


Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr Leu Val His Asn Gly 
                965                 970                 975     


Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala Ser Lys Ser Thr Pro Phe 
            980                 985                 990         


Ser Ile Pro Ser His His Ser Asp  Thr Pro Thr Thr Leu  Ala Ser His 
        995                 1000                 1005             


Ser Thr  Lys Thr Asp Ala Ser  Ser Thr His His Ser  Ser Val Pro 
    1010                 1015                 1020             


Pro Leu  Thr Ser Ser Asn His  Ser Thr Ser Pro Gln  Leu Ser Thr 
    1025                 1030                 1035             


Gly Val  Ser Phe Phe Phe Leu  Ser Phe His Ile Ser  Asn Leu Gln 
    1040                 1045                 1050             


Phe Asn  Ser Ser Leu Glu Asp  Pro Ser Thr Asp Tyr  Tyr Gln Glu 
    1055                 1060                 1065             


Leu Gln  Arg Asp Ile Ser Glu  Met Phe Leu Gln Ile  Tyr Lys Gln 
    1070                 1075                 1080             


Gly Gly  Phe Leu Gly Leu Ser  Asn Ile Lys Phe Arg  Pro Gly Ser 
    1085                 1090                 1095             


Val Val  Val Gln Leu Thr Leu  Ala Phe Arg Glu Gly  Thr Ile Asn 
    1100                 1105                 1110             


Val His  Asp Val Glu Thr Gln  Phe Asn Gln Tyr Lys  Thr Glu Ala 
    1115                 1120                 1125             


Ala Ser  Arg Tyr Asn Leu Thr  Ile Ser Asp Val Ser  Val Ser Asp 
    1130                 1135                 1140             


Val Pro  Phe Pro Phe Ser Ala  Gln Ser Gly Ala Gly  Val Pro Gly 
    1145                 1150                 1155             


Trp Gly  Ile Ala Leu Leu Val  Leu Val Cys Val Leu  Val Ala Leu 
    1160                 1165                 1170             


Ala Ile  Val Tyr Leu Ile Ala  Leu Ala Val Cys Gln  Cys Arg Arg 
    1175                 1180                 1185             


Lys Asn  Tyr Gly Gln Leu Asp  Ile Phe Pro Ala Arg  Asp Thr Tyr 
    1190                 1195                 1200             


His Pro  Met Ser Glu Tyr Pro  Thr Tyr His Thr His  Gly Arg Tyr 
    1205                 1210                 1215             


Val Pro  Pro Ser Ser Thr Asp  Arg Ser Pro Tyr Glu  Lys Val Ser 
    1220                 1225                 1230             


Ala Gly  Asn Gly Gly Ser Ser  Leu Ser Tyr Thr Asn  Pro Ala Val 
    1235                 1240                 1245             


Ala Ala  Ala Ser Ala Asn Leu  
    1250                 1255 


<210>  2
<211>  171
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A truncated MUC1 receptor isoform having nat-PSMGFR and PSIBR at 
       its N-terminus and including the transmembrane and cytoplasmic 
       sequences of a full-length MUC1 receptor which may be cleaved 
       after translation and prior to expression of the receptor on the 
       

<400>  2

Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val 
1               5                   10                  15      


Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp 
            20                  25                  30          


Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr 
        35                  40                  45              


Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe 
    50                  55                  60                  


Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala Leu Leu 
65                  70                  75                  80  


Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu Ile Ala 
                85                  90                  95      


Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu Asp Ile 
            100                 105                 110         


Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro Thr Tyr 
        115                 120                 125             


His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg Ser Pro 
    130                 135                 140                 


Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr Thr 
145                 150                 155                 160 


Asn Pro Ala Val Ala Ala Ala Ser Ala Asn Leu 
                165                 170     


<210>  3
<211>  275
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A truncated MUC1 receptor isoform having nat-PSMGFR + PSIBR + 
       Unique Region at its N-terminus and including the transmembrane 
       and cytoplasmic sequences of a full-length MUC1 receptor

<400>  3

Ala Thr Thr Thr Pro Ala Ser Lys Ser Thr Pro Phe Ser Ile Pro Ser 
1               5                   10                  15      


His His Ser Asp Thr Pro Thr Thr Leu Ala Ser His Ser Thr Lys Thr 
            20                  25                  30          


Asp Ala Ser Ser Thr His His Ser Thr Val Pro Pro Leu Thr Ser Ser 
        35                  40                  45              


Asn His Ser Thr Ser Pro Gln Leu Ser Thr Gly Val Ser Phe Phe Phe 
    50                  55                  60                  


Leu Ser Phe His Ile Ser Asn Leu Gln Phe Asn Ser Ser Leu Glu Asp 
65                  70                  75                  80  


Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln Arg Asp Ile Ser Glu Met 
                85                  90                  95      


Phe Leu Gln Ile Tyr Lys Gln Gly Gly Phe Leu Gly Leu Ser Asn Ile 
            100                 105                 110         


Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu Ala Phe Arg 
        115                 120                 125             


Glu Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr 
    130                 135                 140                 


Lys Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser 
145                 150                 155                 160 


Val Ser Asp Val Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val 
                165                 170                 175     


Pro Gly Trp Gly Ile Ala Leu Leu Val Leu Val Cys Val Leu Val Ala 
            180                 185                 190         


Leu Ala Ile Val Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg 
        195                 200                 205             


Lys Asn Tyr Gly Gln Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His 
    210                 215                 220                 


Pro Met Ser Glu Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro 
225                 230                 235                 240 


Pro Ser Ser Thr Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn 
                245                 250                 255     


Gly Gly Ser Ser Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala Ala Ser 
            260                 265                 270         


Ala Asn Leu 
        275 


<210>  4
<211>  45
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR

<400>  4

Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys 
1               5                   10                  15      


Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val 
            20                  25                  30          


Ser Asp Val Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala 
        35                  40                  45  


<210>  5
<211>  43
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR N+20/C-22

<400>  5

Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu 
1               5                   10                  15      


Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe 
            20                  25                  30          


Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr 
        35                  40              


<210>  6
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR N+12/C-22

<400>  6

Ser Val Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn 
1               5                   10                  15      


Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala 
            20                  25                  30          


Ser Arg Tyr 
        35  


<210>  7
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR N+9/C-30

<400>  7

Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp 
1               5                   10                  15      


Val Glu Thr Gln Phe Asn Gln Tyr 
            20                  


<210>  8
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR N+20/C-41

<400>  8

Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu 
1               5                   10                  15      


Ala Phe Arg Glu Gly Thr Ile Asn 
            20                  


<210>  9
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR N+20/C-27

<400>  9

Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu 
1               5                   10                  15      


Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe 
            20                  25                  30          


Asn Gln Tyr Lys Thr Glu 
        35              


<210>  10
<211>  45
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PSMGFR N+9/C-9

<400>  10

Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp 
1               5                   10                  15      


Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr 
            20                  25                  30          


Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro 
        35                  40                  45  


<210>  11
<211>  426
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  11
atgaagttgt ggctgaactg gattttcctt gtaacacttt taaatggtat ccagtgtgag       60

gtgaagctgg tggagtctgg aggaggcttg gtacagcctg ggggttctct gagactctcc      120

tgtgcaactt ctgggttcac cttcactgat tactacatga gctgggtccg ccagcctcca      180

agaaaggcac ttgagtggtt gggttttatt agaaacaaag ctaatggtta cacagcagag      240

tacagtgcgt ctgtgaaggg tcggttcacc atctccagag atgtttccca aaacctcctc      300

tatcttcaaa tgaacatcct gagagctgag gacagtgcca cttattactg tgcaaaagat      360

tactacggta gtaaccctgc ctggtttgct tactggggcc aagggactct ggtcactgtc      420

tctgca                                                                 426


<210>  12
<211>  142
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Heavy chain - Signal 
       peptide-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  12

Met Lys Leu Trp Leu Asn Trp Ile Phe Leu Val Thr Leu Leu Asn Gly 
1               5                   10                  15      


Ile Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln 
            20                  25                  30          


Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe 
        35                  40                  45              


Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro Arg Lys Ala Leu 
    50                  55                  60                  


Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly Tyr Thr Ala Glu 
65                  70                  75                  80  


Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Val Ser 
                85                  90                  95      


Gln Asn Leu Leu Tyr Leu Gln Met Asn Ile Leu Arg Ala Glu Asp Ser 
            100                 105                 110         


Ala Thr Tyr Tyr Cys Ala Lys Asp Tyr Tyr Gly Ser Asn Pro Ala Trp 
        115                 120                 125             


Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
    130                 135                 140         


<210>  13
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  13
atgaagttgc ctgtgaggct gttggtgctg atgttctgga ttcctgcttc caacagtgat       60

attttgatga cccagactcc actctccctg cctgtcagtc ttggagatca agcctccatc      120

tcttgcagat ctagtcagag cattgtacat agtagtggaa acaccttttt agaatggtac      180

ctgcagaaac ctggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct      240

ggggtcccag acaggttcag tggcagtgga tcagggatag atttcacact caagatcagc      300

agagtggagg ctgaggatct gggagtttat tactgctttc aaggttcaca tgttcctttc      360

acgttcggct cggggacaaa gttggaaata aaa                                   393


<210>  14
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Light chain - Signal 
       peptide-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  14

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 
1               5                   10                  15      


Ser Asn Ser Asp Ile Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val 
            20                  25                  30          


Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile 
        35                  40                  45              


Val His Ser Ser Gly Asn Thr Phe Leu Glu Trp Tyr Leu Gln Lys Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Ile Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys 
            100                 105                 110         


Phe Gln Gly Ser His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  15
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Heavy Chain CDR1

<400>  15
gattactaca tgagc                                                        15


<210>  16
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Heavy Chain CDR1

<400>  16

Asp Tyr Tyr Met Ser 
1               5   


<210>  17
<211>  57
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Heavy Chain CDR2

<400>  17
tttattagaa acaaagctaa tggttacaca gcagagtaca gtgcgtctgt gaagggt          57


<210>  18
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Heavy Chain CDR

<400>  18

Phe Ile Arg Asn Lys Ala Asn Gly Tyr Thr Ala Glu Tyr Ser Ala Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  19
<211>  36
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Heavy Chain CDR3

<400>  19
gattactacg gtagtaaccc tgcctggttt gcttac                                 36


<210>  20
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Heavy Chain CDR3

<400>  20

Asp Tyr Tyr Gly Ser Asn Pro Ala Trp Phe Ala Tyr 
1               5                   10          


<210>  21
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Light Chain CDR1

<400>  21
agatctagtc agagcattgt acatagtagt ggaaacacct ttttagaa                    48


<210>  22
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Light Chain CDR1

<400>  22

Arg Ser Ser Gln Ser Ile Val His Ser Ser Gly Asn Thr Phe Leu Glu 
1               5                   10                  15      


<210>  23
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Light Chain CDR2

<400>  23
aaagtttcca accgattttc t                                                 21


<210>  24
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Light Chain CDR2

<400>  24

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  25
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Light Chain CDR3

<400>  25
tttcaaggtt cacatgttcc tttcacg                                           27


<210>  26
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 17H6 Light Chain CDR3

<400>  26

Phe Gln Gly Ser His Val Pro Phe Thr 
1               5                   


<210>  27
<211>  408
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  27
atggcttggg tgtggacctt gctattcctg atggcagctg cccaaagtgc ccaagcacag       60

atccagttgg tgcagtctgg acctgagctg aagaagcctg gagagacagt caagatctcc      120

tgcaaggctt ctgggtatac cttcacaaac tatggaatga actgggtgaa gcaggctcca      180

ggaaagggtt taaagtggat gggctggata aacacctaca ctggagagcc aacatatgtt      240

ggtgacttca agggacggtt tgccttctct ttggagacct ctgccagcac tgcctatttg      300

cagatcaaca acctcaaaaa tgaggacacg gctacatatt tttgtgttag aggtatccac      360

ggctacgtgg actactgggg ccaaggcacc actctcacag tctcctca                   408


<210>  28
<211>  136
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  28

Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser 
1               5                   10                  15      


Ala Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys 
            20                  25                  30          


Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu 
    50                  55                  60                  


Lys Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val 
65                  70                  75                  80  


Gly Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser 
                85                  90                  95      


Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr 
            100                 105                 110         


Tyr Phe Cys Val Arg Gly Ile His Gly Tyr Val Asp Tyr Trp Gly Gln 
        115                 120                 125             


Gly Thr Thr Leu Thr Val Ser Ser 
    130                 135     


<210>  29
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  29
atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat       60

gttttgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccatc      120

tcttgcagat ctagtcagag cattgtacat agaaatggaa acacctattt agaatggtac      180

ctgcagaaac caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct      240

ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcagc      300

agagtggagg ctgaggatct gggagtttat tactgctttc aaggttcaca tcttccgtgg      360

acgttcggtg gaggcaccaa gctggaaatc aaa                                   393


<210>  30
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  30

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 
1               5                   10                  15      


Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val 
            20                  25                  30          


Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile 
        35                  40                  45              


Val His Arg Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys 
            100                 105                 110         


Phe Gln Gly Ser His Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  31
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Heavy Chain CDR1

<400>  31
aactatggaa tgaac                                                        15


<210>  32
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Heavy Chain CDR1

<400>  32

Asn Tyr Gly Met Asn 
1               5   


<210>  33
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Heavy Chain CDR2

<400>  33
tggataaaca cctacactgg agagccaaca tatgttggtg acttcaaggg a                51


<210>  34
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Heavy Chain CDR2

<400>  34

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Gly Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  35
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Heavy Chain CDR3

<400>  35
ggtatccacg gctacgtgga ctac                                              24


<210>  36
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Heavy Chain CDR3

<400>  36

Gly Ile His Gly Tyr Val Asp Tyr 
1               5               


<210>  37
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Light Chain CDR1

<400>  37
agatctagtc agagcattgt acatagaaat ggaaacacct atttagaa                    48


<210>  38
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Light Chain CDR1

<400>  38

Arg Ser Ser Gln Ser Ile Val His Arg Asn Gly Asn Thr Tyr Leu Glu 
1               5                   10                  15      


<210>  39
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Light Chain CDR2

<400>  39
aaagtttcca accgattttc t                                                 21


<210>  40
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Light Chain CDR2

<400>  40

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  41
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Light Chain CDR3

<400>  41
tttcaaggtt cacatcttcc gtggacg                                           27


<210>  42
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 39H5 Light Chain CDR3

<400>  42

Phe Gln Gly Ser His Leu Pro Trp Thr 
1               5                   


<210>  43
<211>  411
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  43
atggcttggg tgtggacctt gctgttcctg atggcagctg cccaaagtgc ccaagcacag       60

atccagttgg tgcagtctgg acctgagctg aagaagcctg gagagacagt caagatctcc      120

tgcaaggctt ctgggtatac cttcacaaac tatggaatga actgggtgaa gcaggctcca      180

ggaaagggtt taaagtggat gggctggata aacacctaca ctggaaagcc aacatatgct      240

gatgacttca agggacggtt tgccttctct ttggagacct ctgccagcac tgcctatttg      300

cagatcaaca acctcaaaaa tgaggacacg gctacatatt tctgtgcaag agggggacta      360

gatggttact acggctactg gggccaaggc accactctca cagtctcctc a               411


<210>  44
<211>  137
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  44

Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser 
1               5                   10                  15      


Ala Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys 
            20                  25                  30          


Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu 
    50                  55                  60                  


Lys Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Lys Pro Thr Tyr Ala 
65                  70                  75                  80  


Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser 
                85                  90                  95      


Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr 
            100                 105                 110         


Tyr Phe Cys Ala Arg Gly Gly Leu Asp Gly Tyr Tyr Gly Tyr Trp Gly 
        115                 120                 125             


Gln Gly Thr Thr Leu Thr Val Ser Ser 
    130                 135         


<210>  45
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  45
atgagtcctg cccagttcct gtttctgcta gtgctctcga ttcaggaaac caacggtgat       60

gttgtgatgg ctcagacccc actcactttg tcggttacca ttggacaacc agcctccatc      120

tcttgcaaat caagtcagag cctcttacat agtaaaggaa agacatattt gaattggtta      180

ttacagaggc caggccagtc tccaaagctc ctaatctatc tggtgtctaa actggaatct      240

ggagtccctg acaggttcag tggcagtgga tcagggacag atttcacact gaaaatcagc      300

agagtggagg ctgaagattt gggagtttat tactgcttgc aaactacaca ttttccgtgg      360

acgttcggtg gaggcaccaa gctggaaatc aaa                                   393


<210>  46
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  46

Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Ser Ile Gln Glu 
1               5                   10                  15      


Thr Asn Gly Asp Val Val Met Ala Gln Thr Pro Leu Thr Leu Ser Val 
            20                  25                  30          


Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu 
        35                  40                  45              


Leu His Ser Lys Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Leu Leu Ile Tyr Leu Val Ser Lys Leu Glu Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys 
            100                 105                 110         


Leu Gln Thr Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  47
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Heavy Chain CDR1

<400>  47
aactatggaa tgaac                                                        15


<210>  48
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Heavy Chain CDR1

<400>  48

Asn Tyr Gly Met Asn 
1               5   


<210>  49
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Heavy Chain CDR2

<400>  49
tggataaaca cctacactgg aaagccaaca tatgctgatg acttcaaggg a                51


<210>  50
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Heavy Chain CDR2

<400>  50

Trp Ile Asn Thr Tyr Thr Gly Lys Pro Thr Tyr Ala Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  51
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Heavy Chain CDR3

<400>  51
gggggactag atggttacta cggctac                                           27


<210>  52
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Heavy Chain CDR3

<400>  52

Gly Gly Leu Asp Gly Tyr Tyr Gly Tyr 
1               5                   


<210>  53
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Light Chain CDR1

<400>  53
aaatcaagtc agagcctctt acatagtaaa ggaaagacat atttgaat                    48


<210>  54
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Light Chain CDR1

<400>  54

Lys Ser Ser Gln Ser Leu Leu His Ser Lys Gly Lys Thr Tyr Leu Asn 
1               5                   10                  15      


<210>  55
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Light Chain CDR2

<400>  55
ctggtgtcta aactggaatc t                                                 21


<210>  56
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Light Chain CDR2

<400>  56

Leu Val Ser Lys Leu Glu Ser 
1               5           


<210>  57
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Light Chain CDR3

<400>  57
ttgcaaacta cacattttcc gtggacg                                           27


<210>  58
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 3C5 Light Chain CDR3

<400>  58

Leu Gln Thr Thr His Phe Pro Trp Thr 
1               5                   


<210>  59
<211>  420
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  59
atgaagttgt ggctgaactg gattttcctt gtaacacttt taaatggtat ccagtgtgag       60

gtggagctgg tggagtctgg aggaggcttg gtacagcctg ggggttctct gagactctcc      120

tgtgcaactt ctgggttcac cttcactgat cactacatga gctgggtccg ccagcctcca      180

ggaaaggcac ttgagtggtt gggatttatt agaaacaaag ctaatggtta cacaacagag      240

tacagtgcat ctgtgaaggg tcggttcacc atctccagag ataattccca aagcatcctc      300

tatcttcaaa tgaaaaccct gagaactgag gacagtgcca cttattactg tgcaagacct      360

tctgactggg actcctggtt tgcttactgg ggccaaggga ctctggtcac tgtctctgca      420


<210>  60
<211>  140
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  60

Met Lys Leu Trp Leu Asn Trp Ile Phe Leu Val Thr Leu Leu Asn Gly 
1               5                   10                  15      


Ile Gln Cys Glu Val Glu Leu Val Glu Ser Gly Gly Gly Leu Val Gln 
            20                  25                  30          


Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe 
        35                  40                  45              


Thr Asp His Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Ala Leu 
    50                  55                  60                  


Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu 
65                  70                  75                  80  


Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser 
                85                  90                  95      


Gln Ser Ile Leu Tyr Leu Gln Met Lys Thr Leu Arg Thr Glu Asp Ser 
            100                 105                 110         


Ala Thr Tyr Tyr Cys Ala Arg Pro Ser Asp Trp Asp Ser Trp Phe Ala 
        115                 120                 125             


Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
    130                 135                 140 


<210>  61
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  61
atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat       60

gttttgatga cccaaactcc actctccctg cctgtcagtc ttggtgatca agcctccatc      120

tcttgcagat ctagtcagag cattgtacat agtaatggca acacctattt agattggtac      180

ttgcagaaac caggccagtc tccaaagctc ctgatctaca gagtttccaa ccgattttct      240

ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcagc      300

agagtggagg ctgaggatct gggactttat tactgttttc aaggttcaca tgttccgtgg      360

gcgttcggtg gaggcaccaa gctggaaatc aaa                                   393


<210>  62
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  62

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 
1               5                   10                  15      


Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val 
            20                  25                  30          


Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile 
        35                  40                  45              


Val His Ser Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Leu Tyr Tyr Cys 
            100                 105                 110         


Phe Gln Gly Ser His Val Pro Trp Ala Phe Gly Gly Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  63
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Heavy Chain CDR1

<400>  63
gatcactaca tgagc                                                        15


<210>  64
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Heavy Chain CDR1

<400>  64

Asp His Tyr Met Ser 
1               5   


<210>  65
<211>  57
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Heavy Chain CDR2

<400>  65
tttattagaa acaaagctaa tggttacaca acagagtaca gtgcatctgt gaagggt          57


<210>  66
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Heavy Chain CDR2

<400>  66

Phe Ile Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu Tyr Ser Ala Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  67
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Heavy Chain CDR3

<400>  67
ccttctgact gggactcctg gtttgcttac                                        30


<210>  68
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Heavy Chain CDR3

<400>  68

Pro Ser Asp Trp Asp Ser Trp Phe Ala Tyr 
1               5                   10  


<210>  69
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Light Chain CDR1

<400>  69
agatctagtc agagcattgt acatagtaat ggcaacacct atttagat                    48


<210>  70
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Light Chain CDR1

<400>  70

Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Asp 
1               5                   10                  15      


<210>  71
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Light Chain CDR2

<400>  71
agagtttcca accgattttc t                                                 21


<210>  72
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Light Chain CDR2

<400>  72

Arg Val Ser Asn Arg Phe Ser 
1               5           


<210>  73
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Light Chain CDR3

<400>  73
tttcaaggtt cacatgttcc gtgggcg                                           27


<210>  74
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 8A9 Light Chain CDR3

<400>  74

Phe Gln Gly Ser His Val Pro Trp Ala 
1               5                   


<210>  75
<211>  399
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  75
atgggatgga gctatatcat cctctttttg gtcgcaacag ctacaggtgt ccactcccag       60

gtccaactgc agcagtctgg ggctgaactg gtgaagcctg gggcttcagt gaagttgtcc      120

tgcaaggctt ctggctacac cttcaccggc tactttttgt actgggtgaa gcagaggcct      180

ggacaaggcc ttgagtggat tggggggatt aatcctgaca atggtggtat tgacttcaat      240

gagaagttca ggaacaaggc cacactgact gtagacaaat cctccagcac agcctacatg      300

caactcagca gcctgacatc tgaggactct gcggtctatt attgtacatt actaataggg      360

aactattggg gccaaggcac cactctcaca gtctcctca                             399


<210>  76
<211>  133
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  76

Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 
1               5                   10                  15      


Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys 
            20                  25                  30          


Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Gly Tyr Phe Leu Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Gly Ile Asn Pro Asp Asn Gly Gly Ile Asp Phe Asn 
65                  70                  75                  80  


Glu Lys Phe Arg Asn Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser 
                85                  90                  95      


Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 
            100                 105                 110         


Tyr Tyr Cys Thr Leu Leu Ile Gly Asn Tyr Trp Gly Gln Gly Thr Thr 
        115                 120                 125             


Leu Thr Val Ser Ser 
    130             


<210>  77
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  77
atgagtcctg cccagttcct gtttctgtta gtgctctgga ttcgggaaac caatggtgat       60

gttgtgatga cccagactcc actcactttg tcggtaacca ttggacagcc agcctccatc      120

tcttgcaagt caagtcagag cctcttacat agtgatggaa agacatattt gatttggttg      180

ttacagaggc caggccagtc tccaaagcgc ctaatctatc tggtgtctaa actggactct      240

ggagtccctg acaggttcac tggcagtgga tcagggacag atttcacact gaaaatcagc      300

agagtggagg ctgaggattt gggagtttat ttttgctgtc aaggtacaca ttttccgtgg      360

acgttcggtg gaggcaccat gctggaaatc aaa                                   393


<210>  78
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  78

Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg Glu 
1               5                   10                  15      


Thr Asn Gly Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val 
            20                  25                  30          


Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu 
        35                  40                  45              


Leu His Ser Asp Gly Lys Thr Tyr Leu Ile Trp Leu Leu Gln Arg Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys 
            100                 105                 110         


Cys Gln Gly Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Met Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  79
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Heavy Chain CDR1

<400>  79
ggctactttt tgtac                                                        15


<210>  80
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Heavy Chain CDR1

<400>  80

Gly Tyr Phe Leu Tyr 
1               5   


<210>  81
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Heavy Chain CDR2

<400>  81
gggattaatc ctgacaatgg tggtattgac ttcaatgaga agttcaggaa c                51


<210>  82
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Heavy Chain CDR2

<400>  82

Gly Ile Asn Pro Asp Asn Gly Gly Ile Asp Phe Asn Glu Lys Phe Arg 
1               5                   10                  15      


Asn 
    


<210>  83
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Heavy Chain CDR3

<400>  83
ctaataggga actat                                                        15


<210>  84
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Heavy Chain CDR3

<400>  84

Leu Ile Gly Asn Tyr 
1               5   


<210>  85
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Light Chain CDR1

<400>  85
aagtcaagtc agagcctctt acatagtgat ggaaagacat atttgatt                    48


<210>  86
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Light Chain CDR1

<400>  86

Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys Thr Tyr Leu Ile 
1               5                   10                  15      


<210>  87
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Light Chain CDR2

<400>  87
ctggtgtcta aactggactc t                                                 21


<210>  88
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Light Chain CDR2

<400>  88

Leu Val Ser Lys Leu Asp Ser 
1               5           


<210>  89
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Light Chain CDR3

<400>  89
tgtcaaggta cacattttcc gtggacg                                           27


<210>  90
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18G12 Light Chain CDR3

<400>  90

Cys Gln Gly Thr His Phe Pro Trp Thr 
1               5                   


<210>  91
<211>  417
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  91
atgaacttcg ggttcagctt gattttcctt gtccttgttt taaaaggtgt ccagtgtgaa       60

gtgatgctgg tggagtctgg gggaggctta gtgaagcctg gagggtccct gaaactctcc      120

tgtgcagcct ctggattcac tttcagtacc tatgccatgt cttggattcg ccagactcca      180

gagaagaggc tggagtgggt cgcatccatt ggtcgtgctg gttccaccta ctattcagac      240

agtgtgaagg gccgattcac catctccaga gataatgtcc ggaacatcct gtacctgcaa      300

atgagcagtc tgaggtctga ggacacggcc atgtattact gtgctagagg cccgatctac      360

aatgattacg acgagtttgc ttactggggc caagggactc tggtcactgt ctctgca         417


<210>  92
<211>  139
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  92

Met Asn Phe Gly Phe Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly 
1               5                   10                  15      


Val Gln Cys Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys 
            20                  25                  30          


Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 
        35                  40                  45              


Ser Thr Tyr Ala Met Ser Trp Ile Arg Gln Thr Pro Glu Lys Arg Leu 
    50                  55                  60                  


Glu Trp Val Ala Ser Ile Gly Arg Ala Gly Ser Thr Tyr Tyr Ser Asp 
65                  70                  75                  80  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Arg Asn Ile 
                85                  90                  95      


Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr 
            100                 105                 110         


Tyr Cys Ala Arg Gly Pro Ile Tyr Asn Asp Tyr Asp Glu Phe Ala Tyr 
        115                 120                 125             


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
    130                 135                 


<210>  93
<211>  396
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  93
atggaatcac agactcaggt cttcctctcc ctgctgctct gggtatctgg tacctgtggg       60

aacattatga tgacacagtc gccatcatct ctggctgtgt ctgcaggaga aaaggtcact      120

atgagctgta agtccagtca aagtgtttta tacagttcaa atcagaagaa ctatttggcc      180

tggtaccagc agaaaccagg gcagtctcct aaactgctga tctactgggc atccactagg      240

gaatctggtg tccctgatcg cttcacaggc agtggatctg ggacagattt tactcttacc      300

atcagcagtg tacaagctga agacctggca gtttattact gtcatcaata cctctcctcg      360

ctcacgttcg gtgctgggac caagctggag ctgaaa                                396


<210>  94
<211>  132
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  94

Met Glu Ser Gln Thr Gln Val Phe Leu Ser Leu Leu Leu Trp Val Ser 
1               5                   10                  15      


Gly Thr Cys Gly Asn Ile Met Met Thr Gln Ser Pro Ser Ser Leu Ala 
            20                  25                  30          


Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser 
        35                  40                  45              


Val Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln 
    50                  55                  60                  


Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg 
65                  70                  75                  80  


Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp 
                85                  90                  95      


Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr 
            100                 105                 110         


Tyr Cys His Gln Tyr Leu Ser Ser Leu Thr Phe Gly Ala Gly Thr Lys 
        115                 120                 125             


Leu Glu Leu Lys 
    130         


<210>  95
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Heavy Chain CDR1

<400>  95
acctatgcca tgtct                                                        15


<210>  96
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Heavy Chain CDR1

<400>  96

Thr Tyr Ala Met Ser 
1               5   


<210>  97
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Heavy Chain CDR2

<400>  97
tccattggtc gtgctggttc cacctactat tcagacagtg tgaagggc                    48


<210>  98
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Heavy Chain CDR2

<400>  98

Ser Ile Gly Arg Ala Gly Ser Thr Tyr Tyr Ser Asp Ser Val Lys Gly 
1               5                   10                  15      


<210>  99
<211>  36
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Heavy Chain CDR3

<400>  99
ggcccgatct acaatgatta cgacgagttt gcttac                                 36


<210>  100
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Heavy Chain CDR3

<400>  100

Gly Pro Ile Tyr Asn Asp Tyr Asp Glu Phe Ala Tyr 
1               5                   10          


<210>  101
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Light Chain CDR1

<400>  101
aagtccagtc aaagtgtttt atacagttca aatcagaaga actatttggc c                51


<210>  102
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Light Chain CDR1

<400>  102

Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu 
1               5                   10                  15      


Ala 
    


<210>  103
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Light Chain CDR2

<400>  103
tgggcatcca ctagggaatc t                                                 21


<210>  104
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Light Chain CDR2

<400>  104

Trp Ala Ser Thr Arg Glu Ser 
1               5           


<210>  105
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Light Chain CDR3

<400>  105
catcaatacc tctcctcgct cacg                                              24


<210>  106
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 20A10 Light Chain CDR3

<400>  106

His Gln Tyr Leu Ser Ser Leu Thr 
1               5               


<210>  107
<211>  414
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  107
atgaacttcg ggctcagctt gattttcctt gccctcattt taaaaggtgt ccagtgtgag       60

gtgcagctgg tggagtctgg gggagactta gtgaagcctg gagggtccct gaaactctcc      120

tgtgcagcct ctggtttcac tttcagtagt tatggaatgt cttgggttcg ccagactcca      180

gacaagaggc tggagtgggt cgcaaccatt agtaatggtg gtagacacac cttctatcca      240

gacagtgtga aggggcgatt caccatctcc agagacaatg ccaagaacac cctgtatctg      300

caaatgagca gtctgaagtc tgaggacaca gccatgtatt tatgtgtaag acagactggg      360

acggagggct ggtttgctta ctggggccaa gggactctgg tcactgtctc tgca            414


<210>  108
<211>  138
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  108

Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Ala Leu Ile Leu Lys Gly 
1               5                   10                  15      


Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys 
            20                  25                  30          


Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 
        35                  40                  45              


Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu 
    50                  55                  60                  


Glu Trp Val Ala Thr Ile Ser Asn Gly Gly Arg His Thr Phe Tyr Pro 
65                  70                  75                  80  


Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 
                85                  90                  95      


Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met 
            100                 105                 110         


Tyr Leu Cys Val Arg Gln Thr Gly Thr Glu Gly Trp Phe Ala Tyr Trp 
        115                 120                 125             


Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
    130                 135             


<210>  109
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  109
atgagtcctg cccagttcct gtttctgtta gtgctctgga ttcgggaaac caacggtgat       60

gttgtgatga cccagactcc actcactttg tcggttacca ttggacaacc agcctccatc      120

tcttgcaagt caagtcagag cctcttagat agtgatggaa agacatattt gaattggttg      180

ttacagaggc caggccagtc tccaaagcgc ctaatctatc tggtgtctaa actggactct      240

ggagtccctg acaggttcac tggcagtgga tcagggacag atttcacact gaaaatcagc      300

agagtggagg ctgaggattt gggagtttat tattgctggc aaggtacaca ttttcctcag      360

acgttcggtg gaggcaccaa gctggaaatc aaa                                   393


<210>  110
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  110

Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg Glu 
1               5                   10                  15      


Thr Asn Gly Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val 
            20                  25                  30          


Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu 
        35                  40                  45              


Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys 
            100                 105                 110         


Trp Gln Gly Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  111
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Heavy Chain CDR1

<400>  111
agttatggaa tgtct                                                        15


<210>  112
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Heavy Chain CDR1

<400>  112

Ser Tyr Gly Met Ser 
1               5   


<210>  113
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Heavy Chain CDR2

<400>  113
accattagta atggtggtag acacaccttc tatccagaca gtgtgaaggg g                51


<210>  114
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Heavy Chain CDR2

<400>  114

Thr Ile Ser Asn Gly Gly Arg His Thr Phe Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  115
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Heavy Chain CDR3

<400>  115
cagactggga cggagggctg gtttgcttac                                        30


<210>  116
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Heavy Chain CDR3

<400>  116

Gln Thr Gly Thr Glu Gly Trp Phe Ala Tyr 
1               5                   10  


<210>  117
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Light Chain CDR1

<400>  117
aagtcaagtc agagcctctt agatagtgat ggaaagacat atttgaat                    48


<210>  118
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Light Chain CDR1

<400>  118

Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn 
1               5                   10                  15      


<210>  119
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Light Chain CDR2

<400>  119
ctggtgtcta aactggactc t                                                 21


<210>  120
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Light Chain CDR2

<400>  120

Leu Val Ser Lys Leu Asp Ser 
1               5           


<210>  121
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Light Chain CDR3

<400>  121
tggcaaggta cacattttcc tcagacg                                           27


<210>  122
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 25E6 Light Chain CDR3

<400>  122

Trp Gln Gly Thr His Phe Pro Gln Thr 
1               5                   


<210>  123
<211>  399
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  123
atgggatgga gctatatcat cctctttttg gtagcaacag ctacaggtgt ccactcccag       60

gtccaactgc agcagcctgg ggctgaactg gtgcagcctg gggcttcagt gaagttgtcc      120

tgcaaggctt ctggctacac cttcaccggc tactttttgt actgggtgaa gcagaggcct      180

ggacatggcc ttgagtggat tgggggaatt catcctagca atggtgatac tgacttcaat      240

gagaagttca agaacaaggc cacactgact gtagacatat cctccagcac tgcctacatg      300

caactcagca gcctgacatc tgaggactct gcggtctatt attgtacatt actaataggg      360

gtctactggg gccaaggcac cactctcaca gtctcctca                             399


<210>  124
<211>  133
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  124

Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 
1               5                   10                  15      


Val His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Gln 
            20                  25                  30          


Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Gly Tyr Phe Leu Tyr Trp Val Lys Gln Arg Pro Gly His Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Gly Ile His Pro Ser Asn Gly Asp Thr Asp Phe Asn 
65                  70                  75                  80  


Glu Lys Phe Lys Asn Lys Ala Thr Leu Thr Val Asp Ile Ser Ser Ser 
                85                  90                  95      


Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 
            100                 105                 110         


Tyr Tyr Cys Thr Leu Leu Ile Gly Val Tyr Trp Gly Gln Gly Thr Thr 
        115                 120                 125             


Leu Thr Val Ser Ser 
    130             


<210>  125
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  125
atgagtcctg cccagttcct gtttctgtta gtgctctgga ttcgggaaac caacggtgat       60

gttgtgatga cccagactcc actcactttg tcggttacca ttggacaacc agcctccatc      120

tcttgcaagt caagtcagag cctcttacat agtgatggaa agacatattt gatttggttg      180

ttacagaggc caggccagtc tccaaagcgc ctaatctatc tggtgtctaa actggactct      240

ggagtccctg acaggttcac cggcagtgga tcagggacag atttcacact gaaaatcagc      300

agagtggagg ctgaggattt gggagtttat ttttgctgtc aaggtacaca ttttccgtgg      360

acgttcggtg gaggcaccat gctggaaatc aaa                                   393


<210>  126
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  126

Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg Glu 
1               5                   10                  15      


Thr Asn Gly Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val 
            20                  25                  30          


Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu 
        35                  40                  45              


Leu His Ser Asp Gly Lys Thr Tyr Leu Ile Trp Leu Leu Gln Arg Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys 
            100                 105                 110         


Cys Gln Gly Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Met Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  127
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Heavy Chain CDR1

<400>  127
ggctactttt tgtac                                                        15


<210>  128
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Heavy Chain CDR1

<400>  128

Gly Tyr Phe Leu Tyr 
1               5   


<210>  129
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Heavy Chain CDR2

<400>  129
ggaattcatc ctagcaatgg tgatactgac ttcaatgaga agttcaagaa c                51


<210>  130
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Heavy Chain CDR2

<400>  130

Gly Ile His Pro Ser Asn Gly Asp Thr Asp Phe Asn Glu Lys Phe Lys 
1               5                   10                  15      


Asn 
    


<210>  131
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Heavy Chain CDR3

<400>  131
ctaatagggg tctac                                                        15


<210>  132
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Heavy Chain CDR3

<400>  132

Leu Ile Gly Val Tyr 
1               5   


<210>  133
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Light Chain CDR1

<400>  133
aagtcaagtc agagcctctt acatagtgat ggaaagacat atttgatt                    48


<210>  134
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Light Chain CDR1

<400>  134

Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys Thr Tyr Leu Ile 
1               5                   10                  15      


<210>  135
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Light Chain CDR2

<400>  135
ctggtgtcta aactggactc t                                                 21


<210>  136
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Light Chain CDR2

<400>  136

Leu Val Ser Lys Leu Asp Ser 
1               5           


<210>  137
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Light Chain CDR3

<400>  137
tgtcaaggta cacattttcc gtggacg                                           27


<210>  138
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 28F9 Light Chain CDR3

<400>  138

Cys Gln Gly Thr His Phe Pro Trp Thr 
1               5                   


<210>  139
<211>  411
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  139
atgtacttgg gactgaacta tgtattcata gtttttctct taaatggtgt ccagagtgaa       60

gtgaaacttg aggagtctgg aggaggcttg gtgcaacctg ggggatccat gaaactctct      120

tgtgctgcct ctggattcac ttttaatgac gcctggatgg actgggtccg ccagtctcca      180

gagaaggggc ttgagtgggt tgctgaaatt agaagcacag ctaatattca tacaacatac      240

tatgctgagt ctgtccaagg gaggttcacc atctcaagag atgattccaa aagtagtgtc      300

tacctgcaaa tgaacagctt gagagctgaa gacactggca tttattattg taccccatta      360

ctctacggat ttgcttactg gggccaaggg actctggtca ctgtctctgc a               411


<210>  140
<211>  137
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  140

Met Tyr Leu Gly Leu Asn Tyr Val Phe Ile Val Phe Leu Leu Asn Gly 
1               5                   10                  15      


Val Gln Ser Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln 
            20                  25                  30          


Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 
        35                  40                  45              


Asn Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu 
    50                  55                  60                  


Glu Trp Val Ala Glu Ile Arg Ser Thr Ala Asn Ile His Thr Thr Tyr 
65                  70                  75                  80  


Tyr Ala Glu Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser 
                85                  90                  95      


Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr 
            100                 105                 110         


Gly Ile Tyr Tyr Cys Thr Pro Leu Leu Tyr Gly Phe Ala Tyr Trp Gly 
        115                 120                 125             


Gln Gly Thr Leu Val Thr Val Ser Ala 
    130                 135         


<210>  141
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  141
atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat       60

gttgtgatga cccaaagtcc actctccctg cctgtcagtc ttggagatca agcctccatc      120

tcttgcagaa ctagtcagag ccttgtacac agtaatggaa acacctattt acattggcac      180

ctgcagaagc caggccagtc tccaaaggtc ctgatctaca aagtttccag ccgattttct      240

ggggtcccag acaggttcag tggcagtgga tcggggacag atttcacact caagatcagc      300

agagtggagg ctgaggatct gggagtttat ttctgctctc aaaatacaca tgttccgtac      360

acgttcggag gggggaccaa gctggaaata aaa                                   393


<210>  142
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  142

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 
1               5                   10                  15      


Ser Ser Ser Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val 
            20                  25                  30          


Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Thr Ser Gln Ser Leu 
        35                  40                  45              


Val His Ser Asn Gly Asn Thr Tyr Leu His Trp His Leu Gln Lys Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Val Leu Ile Tyr Lys Val Ser Ser Arg Phe Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys 
            100                 105                 110         


Ser Gln Asn Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  143
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy Chain CDR1

<400>  143
gacgcctgga tggac                                                        15


<210>  144
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy Chain CDR1

<400>  144

Asp Ala Trp Met Asp 
1               5   


<210>  145
<211>  57
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy Chain CDR2

<400>  145
gaaattagaa gcacagctaa tattcataca acatactatg ctgagtctgt ccaaggg          57


<210>  146
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy Chain CDR2

<400>  146

Glu Ile Arg Ser Thr Ala Asn Ile His Thr Thr Tyr Tyr Ala Glu Ser 
1               5                   10                  15      


Val Gln Gly 
            


<210>  147
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy Chain CDR3

<400>  147
ttactctacg gatttgctta c                                                 21


<210>  148
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Heavy Chain CDR3

<400>  148

Leu Leu Tyr Gly Phe Ala Tyr 
1               5           


<210>  149
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Light Chain CDR1

<400>  149
agaactagtc agagccttgt acacagtaat ggaaacacct atttacat                    48


<210>  150
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Light Chain CDR1

<400>  150

Arg Thr Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His 
1               5                   10                  15      


<210>  151
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Light Chain CDR2

<400>  151
aaagtttcca gccgattttc t                                                 21


<210>  152
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Light Chain CDR2

<400>  152

Lys Val Ser Ser Arg Phe Ser 
1               5           


<210>  153
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Light Chain CDR3

<400>  153
tctcaaaata cacatgttcc gtacacg                                           27


<210>  154
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 18B4 Light Chain CDR3

<400>  154

Ser Gln Asn Thr His Val Pro Tyr Thr 
1               5                   


<210>  155
<211>  408
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  155
atggaatggc cttgtatctt tctcttcctc ctgtcagtaa ctgaaggtgt ccactcccag       60

gttcagctgc agcagtctgg ggctgagctg gtgaggcctg ggtcctcagt gaagatttcc      120

tgtaaggctt ctggctatgc attcagtacc tactggatga actgggtgaa gcagaggcct      180

ggacagggtc ttgagtggat tggacagatt tatcctggag atagtgatac taactacaat      240

ggaaagttca agggtaaagc cacactgact gcagacaagt cctccaacac agcctacatg      300

cagctcagca gcctaacatc tgaggactct gcggtctttt tctgtgcaag aggtaaccac      360

gcctctatgg actactgggg tcaaggaacc tcagtcaccg tctcctca                   408


<210>  156
<211>  136
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  156

Met Glu Trp Pro Cys Ile Phe Leu Phe Leu Leu Ser Val Thr Glu Gly 
1               5                   10                  15      


Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg 
            20                  25                  30          


Pro Gly Ser Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe 
        35                  40                  45              


Ser Thr Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Gln Ile Tyr Pro Gly Asp Ser Asp Thr Asn Tyr Asn 
65                  70                  75                  80  


Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn 
                85                  90                  95      


Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 
            100                 105                 110         


Phe Phe Cys Ala Arg Gly Asn His Ala Ser Met Asp Tyr Trp Gly Gln 
        115                 120                 125             


Gly Thr Ser Val Thr Val Ser Ser 
    130                 135     


<210>  157
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  157
atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat       60

gttgtgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccatc      120

tcttgcagat ctagtcagag ccttgtacac agtaatggaa acacctattt acattggtac      180

ctgcagaagc caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct      240

ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcagc      300

agagtggagg ctgaggatct gggagtttat ttctgctctc aaaaaacaca tgttccgtgg      360

acgttcggtg gaggcaccaa gctggaaatc aaa                                   393


<210>  158
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  158

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 
1               5                   10                  15      


Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val 
            20                  25                  30          


Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu 
        35                  40                  45              


Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys 
            100                 105                 110         


Ser Gln Lys Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  159
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Heavy Chain CDR1

<400>  159
acctactgga tgaac                                                        15


<210>  160
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Heavy Chain CDR1

<400>  160

Thr Tyr Trp Met Asn 
1               5   


<210>  161
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Heavy Chain CDR2

<400>  161
cagatttatc ctggagatag tgatactaac tacaatggaa agttcaaggg t                51


<210>  162
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Heavy Chain CDR2

<400>  162

Gln Ile Tyr Pro Gly Asp Ser Asp Thr Asn Tyr Asn Gly Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  163
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Heavy Chain CDR3

<400>  163
ggtaaccacg cctctatgga ctac                                              24


<210>  164
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Heavy Chain CDR3

<400>  164

Gly Asn His Ala Ser Met Asp Tyr 
1               5               


<210>  165
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Light Chain CDR1

<400>  165
agatctagtc agagccttgt acacagtaat ggaaacacct atttacat                    48


<210>  166
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Light Chain CDR1

<400>  166

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His 
1               5                   10                  15      


<210>  167
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Light Chain CDR2

<400>  167
aaagtttcca accgattttc t                                                 21


<210>  168
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Light Chain CDR2

<400>  168

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  169
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Light Chain CDR3

<400>  169
tctcaaaaaa cacatgttcc gtggacg                                           27


<210>  170
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 1E4 Light Chain CDR3

<400>  170

Ser Gln Lys Thr His Val Pro Trp Thr 
1               5                   


<210>  171
<211>  411
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  171
atgtacttgg gactgaacta tgtattcata gtttttctct taaatggtgt ccagagtgaa       60

gtgaagcttg aggagtctgg aggaggcttg gtacaacctg gaggatccat gaaactctct      120

tgtgctgcct ctggattcac ttttagtgac gcctggatgg actgggtccg ccagtctcca      180

gagaaggggc ttgaatgggt tgctgaaatt agaagcaaag ctactaatca tgcaacatac      240

tatgctgagt ctgtgaaagg gaggttcacc atctcaagag atgattccaa aagtagtgtc      300

tacctgcaaa tgaacagctt aagagctgaa gacactggca tttattactg taccccccta      360

ctttacgggt ttgcttactg gggccaaggg actctggtca ctgtctctgc a               411


<210>  172
<211>  137
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  172

Met Tyr Leu Gly Leu Asn Tyr Val Phe Ile Val Phe Leu Leu Asn Gly 
1               5                   10                  15      


Val Gln Ser Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln 
            20                  25                  30          


Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 
        35                  40                  45              


Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu 
    50                  55                  60                  


Glu Trp Val Ala Glu Ile Arg Ser Lys Ala Thr Asn His Ala Thr Tyr 
65                  70                  75                  80  


Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser 
                85                  90                  95      


Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr 
            100                 105                 110         


Gly Ile Tyr Tyr Cys Thr Pro Leu Leu Tyr Gly Phe Ala Tyr Trp Gly 
        115                 120                 125             


Gln Gly Thr Leu Val Thr Val Ser Ala 
    130                 135         


<210>  173
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  173
atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat       60

gttgtgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccatc      120

tcttgcagat ctggtcagag ccttgtacac agtaatggac acacctattt acattggtac      180

ctgcagaagc caggccagtc tccaaggctc ctgatctaca aagtttccaa ccgattttct      240

ggggtcccag acaggttcag tggcagtgga tcaagggcag atttcacact caagatcagc      300

agagtggagg ctgaggatct gggagtttat ttctgctctc aaactacaca tgttccgtgg      360

acgttcggtg gaggcaccaa gctggaaatc aaa                                   393


<210>  174
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  174

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 
1               5                   10                  15      


Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val 
            20                  25                  30          


Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu 
        35                  40                  45              


Val His Ser Asn Gly His Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro 
    50                  55                  60                  


Gly Gln Ser Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Arg Ala Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys 
            100                 105                 110         


Ser Gln Thr Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  175
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Heavy Chain CDR1

<400>  175
gacgcctgga tggac                                                        15


<210>  176
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Heavy Chain CDR1

<400>  176

Asp Ala Trp Met Asp 
1               5   


<210>  177
<211>  57
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Heavy Chain CDR2

<400>  177
gaaattagaa gcaaagctac taatcatgca acatactatg ctgagtctgt gaaaggg          57


<210>  178
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Heavy Chain CDR2

<400>  178

Glu Ile Arg Ser Lys Ala Thr Asn His Ala Thr Tyr Tyr Ala Glu Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  179
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Heavy Chain CDR3

<400>  179
ctactttacg ggtttgctta c                                                 21


<210>  180
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Heavy Chain CDR3

<400>  180

Leu Leu Tyr Gly Phe Ala Tyr 
1               5           


<210>  181
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Light Chain CDR1

<400>  181
agatctggtc agagccttgt acacagtaat ggacacacct atttacat                    48


<210>  182
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Light Chain CDR1

<400>  182

Arg Ser Gly Gln Ser Leu Val His Ser Asn Gly His Thr Tyr Leu His 
1               5                   10                  15      


<210>  183
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Light Chain CDR2

<400>  183
aaagtttcca accgattttc t                                                 21


<210>  184
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Light Chain CDR2

<400>  184

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  185
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Light Chain CDR3

<400>  185
tctcaaacta cacatgttcc gtggacg                                           27


<210>  186
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 29H1 Light Chain CDR3

<400>  186

Ser Gln Thr Thr His Val Pro Trp Thr 
1               5                   


<210>  187
<211>  399
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  187
atggaaaggc actggatctt tctcttcctg ttttcagtaa ctgcaggtgt ccactcccag       60

gtccagcttc agcagtctgg ggctgaactg gcaaaacctg gggcctcagt gaagatgtcc      120

tgcaaggctt ctggctacac ctttactagc tactggatgc actgggtaaa acagaggcct      180

ggacagggtc tggaatggat tggatacatt aatcctagca ctggttatac tgagtacaat      240

cagaagttca aggacaaggc cacattgact gcagacaaat cctccagcac agcctacatg      300

caactgagca gcctgacatc tgaggactct gcagtctatt actgtgcaag agcctacatt      360

gactactggg gccaaggcac cactctcaca gtctcctca                             399


<210>  188
<211>  133
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  188

Met Glu Arg His Trp Ile Phe Leu Phe Leu Phe Ser Val Thr Ala Gly 
1               5                   10                  15      


Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Lys 
            20                  25                  30          


Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 
        35                  40                  45              


Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Tyr Ile Asn Pro Ser Thr Gly Tyr Thr Glu Tyr Asn 
65                  70                  75                  80  


Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser 
                85                  90                  95      


Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 
            100                 105                 110         


Tyr Tyr Cys Ala Arg Ala Tyr Ile Asp Tyr Trp Gly Gln Gly Thr Thr 
        115                 120                 125             


Leu Thr Val Ser Ser 
    130             


<210>  189
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  189
atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat       60

gttttgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccttc      120

tcttgcagat ctagtcagag cattgtacat agtaatggaa acacctattt agaatggtac      180

ctgcagaaac caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct      240

ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcaac      300

agagtggagg ctgaggatct gggagtttat tactgctttc aagtttcaca ttttccgtgg      360

acgttcggtg gaggcaccaa gctggaaatc aaa                                   393


<210>  190
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  190

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 
1               5                   10                  15      


Ser Ser Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val 
            20                  25                  30          


Ser Leu Gly Asp Gln Ala Ser Phe Ser Cys Arg Ser Ser Gln Ser Ile 
        35                  40                  45              


Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Asn Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys 
            100                 105                 110         


Phe Gln Val Ser His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  191
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Heavy Chain CDR1

<400>  191
agctactgga tgcac                                                        15


<210>  192
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Heavy Chain CDR1

<400>  192

Ser Tyr Trp Met His 
1               5   


<210>  193
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Heavy Chain CDR2

<400>  193
tacattaatc ctagcactgg ttatactgag tacaatcaga agttcaagga c                51


<210>  194
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Heavy Chain CDR2

<400>  194

Tyr Ile Asn Pro Ser Thr Gly Tyr Thr Glu Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  195
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Heavy Chain CDR3

<400>  195
gcctacattg actac                                                        15


<210>  196
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Heavy Chain CDR3

<400>  196

Ala Tyr Ile Asp Tyr 
1               5   


<210>  197
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Light Chain CDR1

<400>  197
agatctagtc agagcattgt acatagtaat ggaaacacct atttagaa                    48


<210>  198
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Light Chain CDR1

<400>  198

Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 
1               5                   10                  15      


<210>  199
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Light Chain CDR2

<400>  199
aaagtttcca accgattttc t                                                 21


<210>  200
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Light Chain CDR2

<400>  200

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  201
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Light Chain CDR3

<400>  201
tttcaagttt cacattttcc gtggacg                                           27


<210>  202
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 31A1 Light Chain CDR3

<400>  202

Phe Gln Val Ser His Phe Pro Trp Thr 
1               5                   


<210>  203
<211>  411
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  203
atgtacttgg gactgaactg tgtattcata gtttttctct taaaaggtgt ccagagtgaa       60

gtgaagcttg aggagtctgg aggaggcttg gtgcaatctg gaggatccat gaaactctcc      120

tgtgttgcct ctggattcac tttcagtaat tactggatga actgggtccg ccagtctcca      180

gagaaggggc ttgagtgggt tgctgaaatt agattgaaat ctaataatta tgcaatacat      240

tatgcggagt ctgtgaaggg gaggttcacc atctcaagag atgattccaa aagtagtgtc      300

tacctgcaaa tgaacaactt aagagctgaa gacactggca tttattactg taccagggtc      360

ccgggactgg atgcttactg gggccaaggg actctggtca ctgtctctgc a               411


<210>  204
<211>  137
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  204

Met Tyr Leu Gly Leu Asn Cys Val Phe Ile Val Phe Leu Leu Lys Gly 
1               5                   10                  15      


Val Gln Ser Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln 
            20                  25                  30          


Ser Gly Gly Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe 
        35                  40                  45              


Ser Asn Tyr Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu 
    50                  55                  60                  


Glu Trp Val Ala Glu Ile Arg Leu Lys Ser Asn Asn Tyr Ala Ile His 
65                  70                  75                  80  


Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser 
                85                  90                  95      


Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr 
            100                 105                 110         


Gly Ile Tyr Tyr Cys Thr Arg Val Pro Gly Leu Asp Ala Tyr Trp Gly 
        115                 120                 125             


Gln Gly Thr Leu Val Thr Val Ser Ala 
    130                 135         


<210>  205
<211>  393
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  205
atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat       60

gttgtgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccatc      120

tcttgcagat ctagtcagag ccttgtacac agtaatggaa acacctattt acattggtac      180

ctgcagaagc caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct      240

ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcagc      300

agtgtggagg ctgaggatct gggagtttat ttctgctctc aaattacaca tgttccgtac      360

acgttcggag gggggaccaa tctggaaata aaa                                   393


<210>  206
<211>  131
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  206

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 
1               5                   10                  15      


Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val 
            20                  25                  30          


Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu 
        35                  40                  45              


Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro 
    50                  55                  60                  


Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser 
65                  70                  75                  80  


Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
                85                  90                  95      


Leu Lys Ile Ser Ser Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys 
            100                 105                 110         


Ser Gln Ile Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Asn Leu 
        115                 120                 125             


Glu Ile Lys 
    130     


<210>  207
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Heavy Chain CDR1

<400>  207
aattactgga tgaac                                                        15


<210>  208
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Heavy Chain CDR1

<400>  208

Asn Tyr Trp Met Asn 
1               5   


<210>  209
<211>  57
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Heavy Chain CDR2

<400>  209
gaaattagat tgaaatctaa taattatgca atacattatg cggagtctgt gaagggg          57


<210>  210
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Heavy Chain CDR2

<400>  210

Glu Ile Arg Leu Lys Ser Asn Asn Tyr Ala Ile His Tyr Ala Glu Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  211
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Heavy Chain CDR3

<400>  211
gtcccgggac tggatgctta c                                                 21


<210>  212
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Heavy Chain CDR3

<400>  212

Val Pro Gly Leu Asp Ala Tyr 
1               5           


<210>  213
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Light Chain CDR1

<400>  213
agatctagtc agagccttgt acacagtaat ggaaacacct atttacat                    48


<210>  214
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Light Chain CDR1

<400>  214

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His 
1               5                   10                  15      


<210>  215
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Light Chain CDR2

<400>  215
aaagtttcca accgattttc t                                                 21


<210>  216
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Light Chain CDR2

<400>  216

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  217
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Light Chain CDR3

<400>  217
tctcaaatta cacatgttcc gtacacg                                           27


<210>  218
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 32C1 Light Chain CDR3

<400>  218

Ser Gln Ile Thr His Val Pro Tyr Thr 
1               5                   


<210>  219
<211>  423
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  219
atgaaatgca gctgggttat cttcttcctg atggcagtgg ttacaggggt caattcagag       60

gttcagctgc agcagtctgg ggcagacctt gtgaagccag gggcctcagt caagttgtcc      120

tgcacagctt ctggcttcaa cattaaagac acctttatgc actgggtgaa gcagaggcct      180

gaacagggcc tggagtggat tggaaggatt gatcctgcga atggtaatac taaatatgac      240

ccgaaattcc agggcaaggc cactataaca gcagacacat cctccaacac agcctacctg      300

cagctcagca gcctgacatc tgaggacact gccgtctatt actgtgctaa accgtatggt      360

aactacggct attactatgc tttggactac tggggtcaag gaacctcagt caccgtctcc      420

tca                                                                    423


<210>  220
<211>  141
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Heavy chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  220

Met Lys Cys Ser Trp Val Ile Phe Phe Leu Met Ala Val Val Thr Gly 
1               5                   10                  15      


Val Asn Ser Glu Val Gln Leu Gln Gln Ser Gly Ala Asp Leu Val Lys 
            20                  25                  30          


Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile 
        35                  40                  45              


Lys Asp Thr Phe Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp 
65                  70                  75                  80  


Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn 
                85                  90                  95      


Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val 
            100                 105                 110         


Tyr Tyr Cys Ala Lys Pro Tyr Gly Asn Tyr Gly Tyr Tyr Tyr Ala Leu 
        115                 120                 125             


Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
    130                 135                 140     


<210>  221
<211>  381
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  221
atgaggttcc aggttcaggt tctggggctc cttctgctct ggatatcagg tgcccagtgt       60

gatgtccaga taacccagtc tccatcttat cttgctgcat ctcctggaga aaccattact      120

attaattgca gggcaagtaa gagcattagc aaatatttag cctggtatca agagaaacct      180

gggaaaacta ataagcttct tatctactct ggatccactt tgcaatctgg aattccatca      240

aggttcagtg gcagtggatc tggtacagat ttcactctca ccatcagtag cctggagcct      300

gaagattttg caatgtatta ctgtcaacag cataatgaat tcccgtggac gttcggtgga      360

ggcaccaagc tggaaatcaa a                                                381


<210>  222
<211>  127
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Light chain - Signal 
       sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

<400>  222

Met Arg Phe Gln Val Gln Val Leu Gly Leu Leu Leu Leu Trp Ile Ser 
1               5                   10                  15      


Gly Ala Gln Cys Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala 
            20                  25                  30          


Ala Ser Pro Gly Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser Lys Ser 
        35                  40                  45              


Ile Ser Lys Tyr Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn 
    50                  55                  60                  


Lys Leu Leu Ile Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser 
65                  70                  75                  80  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
                85                  90                  95      


Ser Leu Glu Pro Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln His Asn 
            100                 105                 110         


Glu Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
        115                 120                 125         


<210>  223
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Heavy Chain CDR1

<400>  223
gacaccttta tgcac                                                        15


<210>  224
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Heavy Chain CDR1

<400>  224

Asp Thr Phe Met His 
1               5   


<210>  225
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Heavy Chain CDR2

<400>  225
aggattgatc ctgcgaatgg taatactaaa tatgacccga aattccaggg c                51


<210>  226
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Heavy Chain CDR2

<400>  226

Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  227
<211>  39
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Heavy Chain CDR3

<400>  227
ccgtatggta actacggcta ttactatgct ttggactac                              39


<210>  228
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Heavy Chain CDR3

<400>  228

Pro Tyr Gly Asn Tyr Gly Tyr Tyr Tyr Ala Leu Asp Tyr 
1               5                   10              


<210>  229
<211>  33
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Light Chain CDR1

<400>  229
agggcaagta agagcattag caaatattta gcc                                    33


<210>  230
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Light Chain CDR1

<400>  230

Arg Ala Ser Lys Ser Ile Ser Lys Tyr Leu Ala 
1               5                   10      


<210>  231
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Light Chain CDR2

<400>  231
tctggatcca ctttgcaatc t                                                 21


<210>  232
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Light Chain CDR2

<400>  232

Ser Gly Ser Thr Leu Gln Ser 
1               5           


<210>  233
<211>  27
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Light Chain CDR3

<400>  233
caacagcata atgaattccc gtggacg                                           27


<210>  234
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody 45C11 Light Chain CDR3

<400>  234

Gln Gln His Asn Glu Phe Pro Trp Thr 
1               5                   


<210>  235
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tandem repeat domain peptide

<400>  235

Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly 
1               5                   10                  15      


Val Thr Ser Ala 
            20  


<210>  236
<211>  493
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CAR44: CD8/HUMNC2/CD8/4-1BB/CD3

<400>  236

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 
1               5                   10                  15      


His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 
            20                  25                  30          


Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe 
        35                  40                  45              


Thr Phe Ser Gly Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys 
    50                  55                  60                  


Gly Leu Glu Trp Val Ser Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr 
65                  70                  75                  80  


Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 
                85                  90                  95      


Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr 
            100                 105                 110         


Ala Val Tyr Tyr Cys Ala Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr 
        115                 120                 125             


Phe Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Gly Gly 
    130                 135                 140                 


Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val 
145                 150                 155                 160 


Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala 
                165                 170                 175     


Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser 
            180                 185                 190         


Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu 
        195                 200                 205             


Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser 
    210                 215                 220                 


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu 
225                 230                 235                 240 


Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro 
                245                 250                 255     


Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Thr Thr 
            260                 265                 270         


Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln 
        275                 280                 285             


Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala 
    290                 295                 300                 


Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala 
305                 310                 315                 320 


Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr 
                325                 330                 335     


Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln 
            340                 345                 350         


Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser 
        355                 360                 365             


Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys 
    370                 375                 380                 


Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln 
385                 390                 395                 400 


Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu 
                405                 410                 415     


Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg 
            420                 425                 430         


Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met 
        435                 440                 445             


Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly 
    450                 455                 460                 


Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp 
465                 470                 475                 480 


Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 
                485                 490             


<210>  237
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN- A2-1 light chain variable region amino acid sequence

<400>  237

Asp Ile Val Leu Thr Gln Ser Thr Glu Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Tyr Ile 
            20                  25                  30          


His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Phe 
        35                  40                  45              


Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Val Ser Arg Met Glu Ala Glu 
65                  70                  75                  80  


Asp Thr Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Asn Tyr Pro Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Gln Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  238
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-2 light chain variable region amino acid sequence

<400>  238

Asp Ile Val Met Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Ala Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Val Ser Arg Met Glu Ser Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  239
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-1 light chain variable region amino acid sequence

<400>  239

Asp Ile Val Leu Thr Gln Thr Thr Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Tyr Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  240
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-2 light chain variable region amino acid sequence

<400>  240

Asp Ile Val Ile Thr Gln Ser Thr Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Thr 
            20                  25                  30          


Tyr Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  241
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-1 light chain variable region amino acid sequence

<400>  241

Asp Ile Val Ile Thr Gln Thr Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Val Ser Arg Met Glu Ser Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  242
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-2 light chain variable region amino acid sequence

<400>  242

Asp Ile Val Leu Thr Gln Ser Thr Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Val Ser Arg Met Glu Ser Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  243
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-1 light chain variable region amino acid sequence

<400>  243

Asp Ile Val Met Thr Gln Ser Pro Glu Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Tyr Ile 
            20                  25                  30          


His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Phe 
        35                  40                  45              


Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Val Ser Arg Met Glu Ala Glu 
65                  70                  75                  80  


Asp Thr Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Asn Tyr Pro Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Gln Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  244
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-2 light chain variable region amino acid sequence

<400>  244

Asp Ile Val Ile Thr Gln Ser Thr Glu Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Tyr Ile 
            20                  25                  30          


His Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Phe 
        35                  40                  45              


Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Val Ser Arg Met Glu Ala Glu 
65                  70                  75                  80  


Asp Thr Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Asn Tyr Pro Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Gln Ile Lys Arg Ala Asp Ala Ala Pro 
            100                 105                 110         


Thr Val Ser 
        115 


<210>  245
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-1 heavy chain variable region amino acid sequence

<400>  245

Glu Val Lys Leu Gln Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Glu Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gly Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Thr Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Gly Asp Gly Tyr Trp Tyr Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  246
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-2 heavy chain variable region amino acid sequence

<400>  246

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gly Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Thr Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Gly Asp Gly Tyr Trp Tyr Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  247
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-1 heavy chain variable region amino acid sequence

<400>  247

Gln Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Lys Gln Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Asn 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Thr Gly Thr Ala Arg Ala Phe Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Thr Lys Thr Thr Ala Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  248
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-2 heavy chain variable region amino acid sequence

<400>  248

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Lys Gln Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Asn 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Gly Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Thr Gly Thr Ala Arg Ala Phe Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Thr Lys Thr Thr Ala Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  249
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-1 heavy chain variable region amino acid sequence

<400>  249

Glu Val Gln Leu Glu Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Arg Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Thr Gly Thr Thr Ala Ile Leu Asn Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  250
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-2 heavy chain variable region amino acid sequence

<400>  250

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gly Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Thr Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Gly Asp Gly Tyr Trp Tyr Tyr Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  251
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-1 heavy chain variable region amino acid sequence

<400>  251

Glu Val Lys Leu Glu Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Arg Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Thr Gly Thr Thr Ala Ile Leu Asn Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  252
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-2 heavy chain variable region amino acid sequence

<400>  252

Glu Val Gln Leu Glu Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Leu Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Glu Met His Trp Val Lys Gln Thr Pro Val His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile His Pro Gly Ser Gly Gly Thr Ala Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Asn Tyr Gly Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ala Ala Lys Thr Thr Pro Pro Ser Val Tyr 
        115                 120                 


<210>  253
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-3 heavy chain variable region amino acid sequence

<400>  253

Arg Cys Arg Leu Gln Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Arg Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Thr Gly Thr Thr Ala Ile Leu Asn Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Cys Leu 
    130 


<210>  254
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-4 heavy chain variable region amino acid sequence

<400>  254

Glu Val Gln Leu Glu Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Arg Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Thr Gly Thr Thr Ala Ile Leu Asn Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser 
        115                 120                 125             


Val Tyr 
    130 


<210>  255
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-14 light chain variable region amino acid sequence

<400>  255

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Asp Ile Gly Ser Ser 
            20                  25                  30          


Leu Asn Trp Leu Gln Gln Glu Pro Asp Gly Thr Ile Lys Arg Leu Ile 
        35                  40                  45              


Tyr Ala Thr Ser Ser Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly 
    50                  55                  60                  


Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser 
65                  70                  75                  80  


Glu Asp Phe Val Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Ser Pro His 
                85                  90                  95      


Val Arg Cys Trp Asp Gln Ala Gly Ala Glu Thr Gly Cys Cys Thr Asn 
            100                 105                 110         


Cys 
    


<210>  256
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-1 light chain variable region amino acid sequence

<400>  256

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile Arg 
                85                  90                  95      


Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp 
            100                 105         


<210>  257
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-2 light chain variable region amino acid sequence

<400>  257

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu Tyr Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala 
            100                 105                 110         


Pro Thr Val 
        115 


<210>  258
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-29 light chain variable region amino acid sequence

<400>  258

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile Arg 
                85                  90                  95      


Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp 
            100                 105         


<210>  259
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-34 light chain variable region amino acid sequence

<400>  259

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile Arg 
                85                  90                  95      


Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp 
            100                 105         


<210>  260
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-42 light chain variable region amino acid sequence

<400>  260

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Asn Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala 
            100                 105                 110         


Pro Thr Val 
        115 


<210>  261
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-45 light chain variable region amino acid sequence

<400>  261

Asp Ile Gln Met Thr Gln Pro Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Phe 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala 
            100                 105                 110         


Pro Thr Val 
        115 


<210>  262
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-14 heavy chain variable region amino acid sequence

<400>  262

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Tyr Gly Asn Tyr Trp Tyr Phe 
            100                 105 


<210>  263
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-2 heavy chain variable region amino acid sequence

<400>  263

Gln Ile Thr Leu Lys Glu Ser Gly Pro Gly Ile Val Gln Pro Ser Gln 
1               5                   10                  15      


Pro Phe Arg Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
            20                  25                  30          


Gly Ile Gly Val Thr Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Leu Ala Thr Ile Trp Trp Asp Asp Asp Asn Arg Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Val Ser Lys Asp Thr Ser Asn Asn Gln Ala 
65                  70                  75                  80  


Phe Leu Asn Ile Ile Thr Val Glu Thr Ala Asp Thr Ala Ile Tyr Tyr 
                85                  90                  95      


Cys Ala Gln Ser Thr Met Val Thr Ala 
            100                 105 


<210>  264
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-1 heavy chain variable region amino acid sequence

<400>  264

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Tyr Gly Asn Tyr Trp Tyr Phe 
            100                 105 


<210>  265
<211>  127
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-29 heavy chain variable region amino acid sequence


<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be any naturally occurring amino acid

<400>  265

Asp Val Lys Leu Val Glu Ser Gly Gly Asp Leu Xaa Lys Leu Thr Glu 
1               5                   10                  15      


Gly Glu Asp Ile Trp Glu Gly Leu Thr Leu Cys Arg Asp Ser Asp Gln 
            20                  25                  30          


Ser Pro Leu Ala Pro Val Ser Lys Pro Gly Arg Val Val Arg Pro Gln 
        35                  40                  45              


Arg Ser Cys Thr Val Ile Gln Gly Cys Val Leu Arg Leu Gln Thr Ala 
    50                  55                  60                  


His Leu Gln Val Gln Gly Val Leu Gly Ile Val Ser Gly Asp Gly Glu 
65                  70                  75                  80  


Ser Ala Leu His Ser Val Trp Ile Val Gly Ala Thr Thr Ile Thr Ile 
                85                  90                  95      


Asn Gly Cys Asp Gln Leu Gln Pro Leu Leu Trp Ser Leu Ala Asn Pro 
            100                 105                 110         


Arg His Val Ile Ala Thr Glu Ser Glu Ser Arg Gly Cys Thr Gly 
        115                 120                 125         


<210>  266
<211>  104
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-34 heavy chain variable region amino acid sequence

<400>  266

Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Gly Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Ala Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asn Asp Tyr Pro Ala Trp Phe 
            100                 


<210>  267
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-42 heavy chain variable region amino acid sequence

<400>  267

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Arg 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ser Arg Arg Phe Tyr Tyr Asp Tyr Asp 
            100                 105 


<210>  268
<211>  103
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-45 heavy chain variable region amino acid sequence

<400>  268

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Phe Met Ser Trp Val Met Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asn Pro Tyr Asn Gly Asp Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala His 
65                  70                  75                  80  


Ile Glu Leu Arg Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Gly Leu Tyr Gly 
            100             


<210>  269
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-1 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  269

Ser Ala Ser Ser Ser Ile Ser Tyr Ile His 
1               5                   10  


<210>  270
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-2 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  270

Ser Ala Ser Ser Ser Val Ser Tyr Met His 
1               5                   10  


<210>  271
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-1 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  271

Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr 
1               5                   10  


<210>  272
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-2 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  272

Ser Ala Ser Ser Ser Val Ser Tyr Thr Tyr 
1               5                   10  


<210>  273
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-1 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  273

Ser Ala Ser Ser Ser Val Ser Tyr Met His 
1               5                   10  


<210>  274
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-2 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  274

Ser Ala Ser Ser Ser Val Ser Tyr Met His 
1               5                   10  


<210>  275
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-1 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  275

Ser Ala Ser Ser Ser Ile Ser Tyr Ile His 
1               5                   10  


<210>  276
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-2 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  276

Ser Ala Ser Ser Ser Ile Ser Tyr Ile His 
1               5                   10  


<210>  277
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-1 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  277

Gly Thr Ser Asn Leu Ala Ser 
1               5           


<210>  278
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-2 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  278

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  279
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-1 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  279

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  280
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-2 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  280

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  281
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-1 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  281

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  282
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-2 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  282

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  283
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-1 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  283

Gly Thr Ser Asn Leu Ala Ser 
1               5           


<210>  284
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-2 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  284

Gly Thr Ser Asn Leu Ala Ser 
1               5           


<210>  285
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-1 light chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  285

Gln Gln Arg Ser Asn Tyr Pro Phe Thr 
1               5                   


<210>  286
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-2 light chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  286

Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
1               5                   


<210>  287
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-1 light chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  287

Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
1               5                   


<210>  288
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-2 light chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  288

Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
1               5                   


<210>  289
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-1 light chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  289

Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
1               5                   


<210>  290
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-2 light chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  290

Gln Gln Arg Ser Ser Tyr Pro Ser Thr 
1               5                   


<210>  291
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-1 light chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  291

Gln Gln Arg Ser Asn Tyr Pro Phe Thr 
1               5                   


<210>  292
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-2 light chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  292

Gln Gln Arg Ser Asn Tyr Pro Phe Thr 
1               5                   


<210>  293
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-1 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  293

Asn Tyr Gly Met Asn 
1               5   


<210>  294
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-2 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  294

Asn Tyr Gly Met Asn 
1               5   


<210>  295
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-1 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  295

Asn Asn Gly Met Asn 
1               5   


<210>  296
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-2 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  296

Asn Asn Gly Met Asn 
1               5   


<210>  297
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-1 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  297

Asn Tyr Gly Met Asn 
1               5   


<210>  298
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-2 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  298

Asn Tyr Gly Met Asn 
1               5   


<210>  299
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-1 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  299

Asn Tyr Gly Met Asn 
1               5   


<210>  300
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-2 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  300

Asp Tyr Glu Met His 
1               5   


<210>  301
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-3 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  301

Asn Tyr Gly Met Asn 
1               5   


<210>  302
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-4 heavy chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  302

Asn Tyr Gly Met Asn 
1               5   


<210>  303
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-1 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  303

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gly Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  304
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-2 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  304

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gly Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  305
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-1 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  305

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  306
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-2 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  306

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  307
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-1 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  307

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  308
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-2 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  308

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gly Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  309
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-1 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  309

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  310
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-2 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  310

Ala Ile His Pro Gly Ser Gly Gly Thr Ala Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  311
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-3 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  311

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  312
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-4 heavy chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  312

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Val Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  313
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-1 heavy chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  313

Ser Gly Asp Gly Tyr Trp Tyr Tyr Ala 
1               5                   


<210>  314
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-A2-2 heavy chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  314

Ser Gly Asp Gly Tyr Trp Tyr Tyr Ala 
1               5                   


<210>  315
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-1 heavy chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  315

Thr Gly Thr Ala Arg Ala Phe Tyr Ala 
1               5                   


<210>  316
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-C9-2 heavy chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  316

Thr Gly Thr Ala Arg Ala Phe Tyr Ala 
1               5                   


<210>  317
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-1 heavy chain variable complementarity determining region 
       3(CDR3) amino acid sequence

<400>  317

Thr Gly Thr Thr Ala Ile Leu Asn Gly 
1               5                   


<210>  318
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-D7-2 heavy chain variable complementarity determining region3
       (CDR3) amino acid sequence

<400>  318

Ser Gly Asp Gly Tyr Trp Tyr Tyr Ala 
1               5                   


<210>  319
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-1 heavy chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  319

Thr Gly Thr Thr Ala Ile Leu Asn Gly 
1               5                   


<210>  320
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-2 heavy chain variable complementarity determining region 
       3(CDR3) amino acid sequence

<400>  320

Tyr Gly Ser Phe Ala 
1               5   


<210>  321
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-3 heavy chain variable complementarity determining region 
       3 (CDR3) amino acid sequence

<400>  321

Thr Gly Thr Thr Ala Ile Leu Asn Gly 
1               5                   


<210>  322
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-F2-4 heavy chain variable complementarity determining region 
       3(CDR3) amino acid sequence

<400>  322

Thr Gly Thr Thr Ala Ile Leu Asn Gly 
1               5                   


<210>  323
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-14 light chain variable complementarity determining region 1 
       (CDR1) amino acid sequence

<400>  323

Arg Ala Ser Gln Asp Ile Gly Ser Ser Leu Asn 
1               5                   10      


<210>  324
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-1 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  324

Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His 
1               5                   10                  15  


<210>  325
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-2 light chain variable complementarity determining region 
       1 (CDR1) amino acid sequence

<400>  325

Leu Ala Ser Gln Thr Ile Gly Thr Trp Leu Ala 
1               5                   10      


<210>  326
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-29 light chain variable complementarity determining region 1 
       (CDR1) amino acid sequence

<400>  326

Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His 
1               5                   10                  15  


<210>  327
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-34 light chain variable complementarity determining region 1 
       (CDR1) amino acid sequence

<400>  327

Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His 
1               5                   10                  15  


<210>  328
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-42 light chain variable complementarity determining region 1 
       (CDR1) amino acid sequence

<400>  328

Lys Ala Ser Gln Asn Val Gly Thr Asn Val Gly 
1               5                   10      


<210>  329
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-45 light chain variable complementarity determining region 1 
       (CDR1) amino acid sequence

<400>  329

Arg Ala Ser Gly Asn Ile His Asn Phe Leu Ala 
1               5                   10      


<210>  330
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-14 light chain variable complementarity determining region 2 
       (CDR2) amino acid sequence

<400>  330

Ala Thr Ser Ser Leu Asp Ser 
1               5           


<210>  331
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-1 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  331

Leu Val Ser Asn Leu Glu Ser 
1               5           


<210>  332
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-2 light chain variable complementarity determining region 
       2 (CDR2) amino acid sequence

<400>  332

Ala Ala Thr Ser Leu Ala Asp 
1               5           


<210>  333
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-29 light chain variable complementarity determining region 2 
       (CDR2) amino acid sequence

<400>  333

Leu Val Ser Asn Leu Glu Ser 
1               5           


<210>  334
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-34 light chain variable complementarity determining region 2 
       (CDR2) amino acid sequence

<400>  334

Leu Val Ser Asn Leu Glu Ser 
1               5           


<210>  335
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-42 light chain variable complementarity determining region 2 
       (CDR2) amino acid sequence

<400>  335

Ser Ala Ser Tyr Arg Tyr Ser 
1               5           


<210>  336
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-45 light chain variable complementarity determining region 2 
       (CDR2) amino acid sequence

<400>  336

Asn Ala Lys Thr Leu Ala Asp 
1               5           


<210>  337
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-14 heavy chain complementarity determining region 1 (CDR1) 
       amino acid sequence

<400>  337

Ser Tyr Trp Met His 
1               5   


<210>  338
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-1 heavy chain complementarity determining region 1 (CDR1) 
       amino acid sequence

<400>  338

Ser Tyr Trp Met His 
1               5   


<210>  339
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-2 heavy chain complementarity determining region 1 (CDR1) 
       amino acid sequence

<400>  339

Gly Ile Gly Val Thr 
1               5   


<210>  340
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-34 heavy chain complementarity determining region 1 (CDR1) 
       amino acid sequence

<400>  340

Ser Tyr Gly Val His 
1               5   


<210>  341
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-42 heavy chain complementarity determining region 1 (CDR1) 
       amino acid sequence

<400>  341

Ser Phe Gly Met Ser 
1               5   


<210>  342
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-45 heavy chain complementarity determining region 1 (CDR1) 
       amino acid sequence

<400>  342

Gly Tyr Phe Met Ser 
1               5   


<210>  343
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-14 heavy chain complementarity determining region 2 (CDR2) 
       amino acid sequence

<400>  343

Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Ser 
    


<210>  344
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-1 heavy chain complementarity determining region 2 (CDR2) 
       amino acid sequence

<400>  344

Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Ser 
    


<210>  345
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-17-2 heavy chain complementarity determining region 2 (CDR2) 
       amino acid sequence

<400>  345

Thr Ile Trp Trp Asp Asp Asp Asn Arg Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  346
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-29 heavy chain complementarity determining region 2 (CDR2) 
       amino acid sequence

<400>  346

Gly Ile Val Ser Gly Asp Gly Glu Ser Ala Leu His Ser Val Trp Ile 
1               5                   10                  15      


Val Gly 
        


<210>  347
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-34 heavy chain complementarity determining region 2 (CDR2) 
       amino acid sequence

<400>  347

Val Ile Trp Gly Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile Ser 
1               5                   10                  15      


<210>  348
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-42 heavy chain complementarity determining region 2 (CDR2) 
       amino acid sequence

<400>  348

Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  349
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MIN-45 heavy chain complementarity determining region 2 (CDR2) 
       amino acid sequence

<400>  349

Arg Ile Asn Pro Tyr Asn Gly Asp Thr Phe Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  350
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 heavy chain variable region sequence

<400>  350

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ser Thr Ile Ser Gly Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Asp Asn Tyr Gly Arg Asn Tyr Asp Tyr Gly Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  351
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 heavy chain variable complementarity determining 
       regions 1 (CDR1) sequence

<400>  351

Arg Tyr Gly Met Ser 
1               5   


<210>  352
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 heavy chain variable complementarity determining 
       regions 2 (CDR2) sequence

<400>  352

Thr Ile Ser Gly Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  353
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 heavy chain variable complementarity determining 
       regions 3 (CDR3) sequence

<400>  353

Asp Asn Tyr Gly Arg Asn Tyr Asp Tyr Gly Met Asp Tyr 
1               5                   10              


<210>  354
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 light chain variable region sequence

<400>  354

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Thr Cys Ser Ala Thr Ser Ser Val Ser Tyr Ile 
            20                  25                  30          


His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Ser Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 
65                  70                  75                  80  


Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser Ser Pro Phe Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105     


<210>  355
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 light chain variable complementarity determining 
       regions 1 (CDR1) sequence

<400>  355

Ser Ala Thr Ser Ser Val Ser Tyr Ile His 
1               5                   10  


<210>  356
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 light chain variable complementarity determining 
       regions 2 (CDR2) sequence

<400>  356

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  357
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 light chain variable complementarity determining 
       regions 3 (CDR3) sequence

<400>  357

Gln Gln Arg Ser Ser Ser Pro Phe Thr 
1               5                   


<210>  358
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 heavy chain variable region sequence

<400>  358

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr Phe Asp Val Trp Gly 
            100                 105                 110         


Lys Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  359
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 heavy chain variable complementarity determining 
       regions 1 (CDR1) sequence

<400>  359

Gly Tyr Ala Met Ser 
1               5   


<210>  360
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 heavy chain variable complementarity determining 
       regions 2 (CDR2) sequence

<400>  360

Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  361
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 heavy chain variable complementarity determining 
       regions 3 (CDR3) sequence

<400>  361

Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr Phe Asp Val 
1               5                   10          


<210>  362
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 light chain variable region sequence

<400>  362

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn 
65                  70                  75                  80  


Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105                 110         


Thr 
    


<210>  363
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 light chain variable complementarity determining 
       regions 1 (CDR1) sequence

<400>  363

Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His 
1               5                   10                  15  


<210>  364
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 light chain variable complementarity determining 
       regions 2 (CDR2) sequence

<400>  364

Leu Ala Ser Asn Leu Glu Ser 
1               5           


<210>  365
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 light chain variable complementarity determining 
       regions 3 (CDR3) sequence

<400>  365

Gln His Ser Arg Glu Leu Pro Phe Thr 
1               5                   


<210>  366
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 light chain variable complementarity determining 
       regions 3 (CDR3) sequence

<400>  366

Leu Gln Ser Lys Asn Phe Pro Pro Thr 
1               5                   


<210>  367
<211>  507
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pSECTag2 C2 scFV-FC

<400>  367

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 
1               5                   10                  15      


Gly Ser Thr Gly Asp Ala Ala Gln Pro Ala Glu Val Gln Leu Val Glu 
            20                  25                  30          


Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys 
        35                  40                  45              


Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ala Met Ser Trp Val Arg 
    50                  55                  60                  


Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ser Ser Gly 
65                  70                  75                  80  


Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile 
                85                  90                  95      


Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu 
            100                 105                 110         


Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Gly Gly Asp 
        115                 120                 125             


Asn Tyr Tyr Glu Tyr Phe Asp Val Trp Gly Lys Gly Thr Thr Val Thr 
    130                 135                 140                 


Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
145                 150                 155                 160 


Gly Ser Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser 
                165                 170                 175     


Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser 
            180                 185                 190         


Thr Ser Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln 
        195                 200                 205             


Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val 
    210                 215                 220                 


Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
225                 230                 235                 240 


Ile Asn Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His 
                245                 250                 255     


Ser Arg Glu Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile 
            260                 265                 270         


Lys Arg Thr Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 
        275                 280                 285             


Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 
    290                 295                 300                 


Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 
305                 310                 315                 320 


Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 
                325                 330                 335     


Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 
            340                 345                 350         


Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 
        355                 360                 365             


Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 
    370                 375                 380                 


Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 
385                 390                 395                 400 


Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu 
                405                 410                 415     


Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 
            420                 425                 430         


Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 
        435                 440                 445             


Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 
    450                 455                 460                 


Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 
465                 470                 475                 480 


Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 
                485                 490                 495     


Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
            500                 505         


<210>  368
<211>  501
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pSECTag2 E6 scFV-FC

<400>  368

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 
1               5                   10                  15      


Gly Ser Thr Gly Asp Ala Ala Gln Pro Ala Glu Val Gln Leu Val Glu 
            20                  25                  30          


Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys 
        35                  40                  45              


Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr Gly Met Ser Trp Val Arg 
    50                  55                  60                  


Gln Ala Pro Gly Lys Arg Leu Glu Trp Val Ser Thr Ile Ser Gly Gly 
65                  70                  75                  80  


Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile 
                85                  90                  95      


Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu 
            100                 105                 110         


Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Asp Asn Tyr Gly 
        115                 120                 125             


Arg Asn Tyr Asp Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Leu Val 
    130                 135                 140                 


Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
145                 150                 155                 160 


Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu 
                165                 170                 175     


Ser Pro Gly Glu Arg Ala Thr Leu Thr Cys Ser Ala Thr Ser Ser Val 
            180                 185                 190         


Ser Tyr Ile His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Arg Leu 
        195                 200                 205             


Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe 
    210                 215                 220                 


Ser Gly Ser Gly Ser Gly Ser Asp Tyr Thr Leu Thr Ile Ser Ser Leu 
225                 230                 235                 240 


Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser Ser 
                245                 250                 255     


Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Glu Pro Lys 
            260                 265                 270         


Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 
        275                 280                 285             


Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 
    290                 295                 300                 


Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 
305                 310                 315                 320 


Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 
                325                 330                 335     


Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 
            340                 345                 350         


Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 
        355                 360                 365             


Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 
    370                 375                 380                 


Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 
385                 390                 395                 400 


Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 
                405                 410                 415     


Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 
            420                 425                 430         


Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 
        435                 440                 445             


Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 
    450                 455                 460                 


Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 
465                 470                 475                 480 


Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 
                485                 490                 495     


Leu Ser Pro Gly Lys 
            500     


<210>  369
<211>  249
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C2 scFV (VH-VL) sequence

<400>  369

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr Phe Asp Val Trp Gly 
            100                 105                 110         


Lys Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 
        115                 120                 125             


Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Leu Thr Gln Ser Pro 
    130                 135                 140                 


Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg 
145                 150                 155                 160 


Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Tyr 
                165                 170                 175     


Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser 
            180                 185                 190         


Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
        195                 200                 205             


Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Thr Ala 
    210                 215                 220                 


Asn Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro Phe Thr Phe Gly Gly 
225                 230                 235                 240 


Gly Thr Lys Val Glu Ile Lys Arg Thr 
                245                 


<210>  370
<211>  249
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized E6 scFV (VL-VH) sequence

<400>  370

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn 
65                  70                  75                  80  


Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Leu Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105                 110         


Thr Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
        115                 120                 125             


Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
    130                 135                 140                 


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
145                 150                 155                 160 


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
                165                 170                 175     


Ser Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
            180                 185                 190         


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
        195                 200                 205             


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
    210                 215                 220                 


Ala Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr Phe Asp Val Trp Gly 
225                 230                 235                 240 


Lys Gly Thr Thr Val Thr Val Ser Ser 
                245                 


<210>  371
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C3 heavy chain variable region sequence

<400>  371

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Val Ile Ser Thr Phe Ser Gly Asn Thr Asn Phe Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Asp Tyr Tyr Gly Pro Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Leu Thr Val Ser Ser 
        115                 


<210>  372
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C3 heavy chain variable complementarity determining 
       regions 1 (CDR1) sequence

<400>  372

Asp Tyr Ala Met Asn 
1               5   


<210>  373
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C3 heavy chain variable complementarity determining 
       regions 2 (CDR2) sequence

<400>  373

Val Ile Ser Thr Phe Ser Gly Asn Thr Asn Phe Asn Gln Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  374
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C3 heavy chain variable complementarity determining 
       regions 3 (CDR3) sequence

<400>  374

Ser Asp Tyr Tyr Gly Pro Tyr Phe Asp Tyr 
1               5                   10  


<210>  375
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C3 light chain variable region sequence

<400>  375

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg Thr 
        


<210>  376
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C3 light chain variable complementarity determining 
       regions 1 (CDR1) sequence

<400>  376

Arg Ser Ser Gln Thr Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 
1               5                   10                  15      


<210>  377
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C3 light chain variable complementarity determining 
       regions 2 (CDR2) sequence

<400>  377

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  378
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C3 light chain variable complementarity determining 
       regions 3 (CDR3) sequence

<400>  378

Phe Gln Gly Ser His Val Pro Phe Thr 
1               5                   


<210>  379
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C8 heavy chain variable region sequence

<400>  379

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr Trp Gly Lys Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  380
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C8 heavy chain variable complementarity determining 
       region 1 (CDR1) sequence

<400>  380

Gly Tyr Ala Met Ser 
1               5   


<210>  381
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C8 heavy chain variable complementarity determining 
       region 2 (CDR2) sequence

<400>  381

Thr Ile Ser Ser Gly Gly Thr Tyr Ile Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  382
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C8 heavy chain variable complementarity determining 
       region 3 (CDR3) sequence

<400>  382

Leu Gly Gly Asp Asn Tyr Tyr Glu Tyr 
1               5                   


<210>  383
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C8 light chain variable region sequence

<400>  383

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ile Arg 
                85                  90                  95      


Glu Leu Thr Arg Ser Glu Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg Thr 
        


<210>  384
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C8 light chain variable complementarity determining 
       region 1 (CDR1) sequence

<400>  384

Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met 
1               5                   10                  


<210>  385
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C8 light chain variable complementarity determining 
       region 2 (CDR2) sequence

<400>  385

Leu Val Ser Asn Leu Glu Ser 
1               5           


<210>  386
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized C8 light chain variable complementarity determining 
       region 3 (CDR3) sequence

<400>  386

Gln His Ile Arg Glu Leu Thr Arg Ser Glu 
1               5                   10  


